NG2–ITGA4 in KMT2A-rearranged B-ALL: biology, not yet a treatment test

NG2 and ITGA4 mark a mechanistic vulnerability in experimental B-ALL models—not a validated treatment assay.

Primary source: Alba Rubio-Gayarre, Meritxell Vinyoles, Juan Ramón Tejedor et al. NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab. Blood, online 23 June 2026. DOI 10.1182/blood.2025031693. PubMed record.

From antigen expression to biology

NG2 (CSPG4) is a KMT2A-fusion-associated cell-surface proteoglycan. Rubio-Gayarre and collaborators investigated whether NG2 and integrin-α4 (ITGA4) together explain part of the aggressive phenotype of KMT2A-rearranged B-cell acute lymphoblastic leukaemia. Their experiments connected the axis to Rho GTPase activity, migration and proliferation. Genetic disruption of the two proteins delayed disease and prolonged survival in immunodeficient-mouse models.

Importantly, the clinically approved ITGA4-targeting antibody natalizumab reduced leukaemia progression and potentiated chemotherapy in patient-derived xenograft models. These are mechanistic and translational findings; the abstract does not establish patient response rates, a clinical trial outcome, or a validated NG2/ITGA4 therapeutic selection assay.

Original CFCM conceptual diagram from KMT2A rearrangement to NG2, ITGA4, Rho GTPase signalling and experimental natalizumab blockade, explicitly preclinical. — **Figure 1 (CFCM original schematic).** Conceptual mechanism distilled from the study; not reproduced from the paper. Patient treatment efficacy has not been shown.

What should a cytometry laboratory take from this?

An antigen can have three very different roles: biological phenotype, mechanistic vulnerability and clinically validated biomarker. Before treating NG2 intensity as actionable, a laboratory would need antibody specificity, gating denominator, analytic reproducibility, sample-type compatibility, inter-laboratory agreement and a validated decision threshold. Reagent-level positivity cannot substitute for molecular KMT2A testing. NG2 expression alone neither identifies all KMT2A-r disease nor proves an individual patient will respond to ITGA4 blockade.

Evidence boundary

Natalizumab is approved for other conditions; that does not establish safety or efficacy for KMT2A-r B-ALL. The reported synergy is experimental, not a treatment recommendation. This CFCM piece does not claim a CE-IVD companion diagnostic or regulatory authorisation for this indication. Published preclinical work should not be promoted as a patient treatment option.

Daily Learning Pill — expression is not clinical utility

Expression tests whether a marker can be reliably measured; mechanism tests whether changing its pathway changes biology; utility tests whether using the measurement improves patient decisions or outcomes. Flow cytometry may contribute to the first question, while this study adds experimental support for the second. The third remains open. Academy reuse: KMT2A-r B-ALL / phenotype versus biomarker.